| Outcome Measures: |
Primary: Maximum (peak) plasma drug concentration(Cmax), Maximum (peak) plasma drug concentration, 0 hour（pre-dose,within 30mins） to 72 hours after administration|Area under the plasma concentration-time curve from time zero to time t (AUC0-t), The area under the plasma concentration curve from 0 to 72 h, 0 hour（pre-dose,within 30mins） to 72 hours after administration | Secondary: Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞), The area under the plasma concentration curve from 0 to ∞, 0 hour（pre-dose,within 30mins） to infinity after administration|Time to reach maximum plasma concentration following drug administration (Tmax), Time to maximum concentration, 0 hour（pre-dose,within 30mins） to 72 hours after administration|Elimination half-life (t1/2), Elimination half-life, 0 hour（pre-dose,within 30mins） to 72 hours after administration|Apparent total body clearance (CL/F), Apparent total body clearance, 0 hour（pre-dose,within 30mins） to 72 hours after administration|Apparent volume of distribution (Vd/F), Apparent volume of distribution, 0 hour（pre-dose,within 30mins） to 72 hours after administration|Adverse Event, Serious Adverse Event, Monitor the safety indicators of subjects during the trial, Up to day 4 after the second dose.
|
